ETFELA: Difference between revisions
Appearance
Content deleted Content added
pubchem |
|||
Line 31: | Line 31: | ||
== See also == |
== See also == |
||
* [[ECPLA]] |
* [[ECPLA]] |
||
* [[EIPLA]] |
|||
* [[Methylisopropyllysergamide]] |
* [[Methylisopropyllysergamide]] |
||
Latest revision as of 23:33, 3 October 2024
Clinical data | |
---|---|
Other names | LA-CH2CF3 |
Identifiers | |
| |
PubChem CID | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C20H22F3N3O |
Molar mass | 377.411 g·mol−1 |
3D model (JSmol) | |
| |
|
ETFELA (N-ethyl-N-(2,2,2-trifluoroethyl)lysergamide) is an analog of lysergic acid diethylamide (LSD) first synthesised by Jason C. Parrish as part of the research team led by David E. Nichols. In studies in vitro, it was found to be slightly more potent than LSD itself.[1][2]
See also
[edit]References
[edit]- ^ Nichols DE (2012). "Structure-activity relationships of serotonin 5-HT2A agonists". Wiley Interdisciplinary Reviews: Membrane Transport and Signaling. 1 (5): 559–579. doi:10.1002/wmts.42.
- ^ Nichols DE (2017). "Chemistry and Structure-Activity Relationships of Psychedelics". Current Topics in Behavioral Neurosciences. 36: 1–43. doi:10.1007/7854_2017_475. ISBN 978-3-662-55878-2. PMID 28401524. S2CID 4396184.